IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. (Q53925120)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

title

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

immunotherapy

1 reference

based on heuristic

inferred from title

author

Jeffrey S. Miller

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Bruce R Blazar

series ordinal

6

object named as

Blazar BR

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Angela Panoskaltsis-Mortari

series ordinal

8

object named as

Panoskaltsis-Mortari A

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

author name string

Burns LJ

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Weisdorf DJ

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

DeFor TE

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Vesole DH

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Repka TL

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Burger SR

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Keever-Taylor CA

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

Zhang MJ

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

language of work or name

English

0 references

publication date

1 July 2003

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

published in

Bone Marrow Transplantation

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

volume

32

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

page(s)

177-186

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

cites work

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

The Use of a Sequential High Dose Recombinant Interleukin 2 Regimen After Autologous Bone Marrow Transplantation Does Not Improve the Disease Free Survival of Patients with Acute Leukemia Transplanted in First Complete Remission

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

21 January 2018

Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: a prospective, comparative trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704086

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BMT.1704086

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

PubMed publication ID

12838283

1 reference

stated in

Europe PubMed Central

PubMed publication ID

12838283

retrieved

22 May 2018

reference URL

http://europepmc.org/abstract/MED/12838283

ResearchGate publication ID

10681111

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53925120&oldid=2212324801"